Review of Operations We are pleased to present the Group’s Annual Report for the financial year ended 30 June 2023 and provide an update on further strategic and operational progress since year end. BUSINESS OVERVIEW INOVIQ Ltd (ASX:IIQ) (INOVIQ®) is developing and commercialising next-generation exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO‐NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. Exosome diagnostic pipeline building EXO-NET commercial partnerships advancing 5 Annual Report 2023
RkJQdWJsaXNoZXIy MjE2NDg3